Giuseppe Luigi Banna

Honorary Associate Professor

University of Portsmouth

United Kingdom

Research Interests

Explore related searches

Professors in United Kingdom

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Giuseppe Luigi Banna is an Honorary Associate Professor at the University of Portsmouth, UK. His research focuses on oncology, particularly personalized care for lung and prostate cancers, as well as the prognostic factors in metastatic renal cell carcinoma. His recent publications explore innovative treatment options and disparities in cancer care, significantly contributing to the field of cancer management and patient outcomes.

Articles (10)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Collaborators (6)

Kounosuke Watabe

Wake Forest School of Medicine

UNITED STATES

View details

Alfredo Addeo

University Hospital of Geneva

SWITZERLAND

View details

Kerui Wu

Assistant Professor

University of North Carolina at Greensboro

UNITED STATES

View details

Paolo Zucali

Associate Professor of Medical Oncology

Humanitas University

ITALY

View details

Federico Quaini

Adjunct Professor

University of Parma

ITALY

View details

Nikhil Vasdev

Professor and Chair of Robotic Surgery and Urology

University of Hertfordshire

UNITED KINGDOM

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Giuseppe Luigi Banna

Research Interests

Explore related searches

Contact this professor

About

Articles (10)

Role of Hb to RDW ratio in metastatic renal cell carcinoma patients treated with first-line immunotherapy combinations

Personalized care for patients with EGFR‐mutant nonsmall cell lung cancer: Navigating early to advanced disease management

Ghrelin-induced neuronal NPY promotes brain metastasis in lung cancer patients with low BMI

Investigating the Latest Evidence from Phase III Trials Supporting Treatment Options for De novo Clinically Lymph Node-Positive Hormone-Sensitive Prostate Cancer

Magnetic Resonance or Computed Tomography and Bone Scan for Staging Metastatic Hormone–Sensitive Prostate Cancer

Prognostic Impact of IMDC Category Shift From Baseline to Nivolumab Initiation in Metastatic Renal Cell Carcinoma: A Sub-Analysis of the MEET-URO 15 Study

Prognostic Value of G8 Geriatric Screening and Meet-URO Scores in Metastatic Renal Cell Carcinoma Patients Receiving First-Line Ipilimumab-Nivolumab Combination Immunotherapy

Spotlight on Lung Cancer Disparities in India

The prognostic value of the haemoglobin/red cell distribution width ratio in a cohort of pre-treated patients with renal cell carcinoma receiving nivolumab

177Lu-PSMA-617 for metastatic prostate cancer in India

Collaborators (6)

Kounosuke Watabe

Alfredo Addeo

Kerui Wu

Paolo Zucali

Federico Quaini

Nikhil Vasdev

Make your next move.